Skip to content
10-Q

Quarterly Report

KERYX BIOPHARMACEUTICALS INC

0001114220-18-000090

← back to feed
Filed
Aug 9, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2018 · Jul 31, 2018 120.46M sh
Capex Q2 2018 · Jun 30, 2018 $52K
Capex Q2 2018 · Jun 30, 2017 $420K
Operating Cash Flow Q2 2018 · Jun 30, 2018 −$54.79M
Operating Cash Flow Q2 2018 · Jun 30, 2017 −$44.16M
Cash And Equivalents Q2 2018 · Jun 30, 2018 $49.46M
Cash And Equivalents Q2 2018 · Dec 31, 2017 $93.53M
Cash And Equivalents Q2 2018 · Jun 30, 2017 $140.53M
Cash And Equivalents Q2 2018 · Dec 31, 2016 $111.81M
Stockholders Equity Q2 2018 · Jun 30, 2018 −$41.19M
Stockholders Equity Q2 2018 · Dec 31, 2017 −$14.1M
Current Liabilities Q2 2018 · Jun 30, 2018 $55.05M
Current Liabilities Q2 2018 · Dec 31, 2017 $45.42M
Total Liabilities Q2 2018 · Jun 30, 2018 $186.84M
Total Liabilities Q2 2018 · Dec 31, 2017 $172.97M
Current Assets Q2 2018 · Jun 30, 2018 $125.61M
Current Assets Q2 2018 · Dec 31, 2017 $141.57M
Total Assets Q2 2018 · Jun 30, 2018 $145.65M
Total Assets Q2 2018 · Dec 31, 2017 $158.87M
Sga Expense Q2 2018 · Jun 30, 2018 $28.71M
Sga Expense Q2 2018 · Jun 30, 2018 $54.55M
Sga Expense Q2 2018 · Jun 30, 2017 $24.99M
Sga Expense Q2 2018 · Jun 30, 2017 $48.09M
Rd Expense Q2 2018 · Jun 30, 2018 $8.77M
Rd Expense Q2 2018 · Jun 30, 2018 $17.16M
Rd Expense Q2 2018 · Jun 30, 2017 $9.01M
Rd Expense Q2 2018 · Jun 30, 2017 $15.78M
Net Income Q2 2018 · Jun 30, 2018 −$21.52M
Net Income Q2 2018 · Jun 30, 2018 −$43.41M
Net Income Q2 2018 · Jun 30, 2017 −$86.5M
Net Income Q2 2018 · Jun 30, 2017 −$109.51M
Operating Income Q2 2018 · Jun 30, 2018 −$20.15M
Operating Income Q2 2018 · Jun 30, 2018 −$42.9M
Operating Income Q2 2018 · Jun 30, 2017 −$23.85M
Operating Income Q2 2018 · Jun 30, 2017 −$46.96M
Cost Of Revenue Q2 2018 · Jun 30, 2018 $7.43M
Cost Of Revenue Q2 2018 · Jun 30, 2018 $17.03M
Cost Of Revenue Q2 2018 · Jun 30, 2017 $4.38M
Cost Of Revenue Q2 2018 · Jun 30, 2017 $8.65M